Ipilimumab

CHEMBL1789844 Phase 4 Approuvé Antibody
Half-Life
14.7 days
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This immunotherapy drug is a checkpoint inhibitor that blocks CTLA-4, a protein on immune T-cells that normally acts as a brake on immune activity. By releasing this brake, it allows the immune system to mount a more powerful attack against cancer cells. It is used to treat advanced melanoma, kidney cancer, lung cancer, and other malignancies, often in combination with another checkpoint inhibitor.

Aires thérapeutiques

Classes de médicaments

Mécanisme d'action

Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics (PK)

Half-Life 14.7 days

Pharmacodynamics (PD)

Mécanisme

Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This immunotherapy drug is a checkpoint inhibitor that blocks CTLA-4, a protein on immune T-cells that normally acts as a brake on immune activity. By releasing this brake, it allows the immune system to mount a more powerful attack against cancer cells. It is used to treat advanced melanoma, kidney cancer, lung cancer, and other malignancies, often in combination with another checkpoint inhibitor.

Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Key pharmacokinetic parameters for Ipilimumab: Half-life: 14.7 days.

Yes, Ipilimumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1789844. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.